透析前慢性腎臓病における左室肥大に関する心筋バイオマーカーを用いた評価

  • 木村 友則
    りんくう医療センター市立泉佐野病院腎臓内科
  • 飯尾 健一郎
    りんくう医療センター市立泉佐野病院腎臓内科 大阪大学医学部附属病院老年・腎臓内科
  • 小尾 佳嗣
    りんくう医療センター市立泉佐野病院腎臓内科

書誌事項

タイトル別名
  • Left ventricular hypertrophy in predialysis chronic kidney disease: Impact of cardiomuscular stress markers
  • トウセキゼン マンセイ ジンゾウビョウ ニ オケル サシツ ヒダイ ニ カンスル シンキン バイオマーカー オ モチイタ ヒョウカ
  • Impact of cardiomuscular stress markers

この論文をさがす

抄録

Left ventricular hypertrophy (LVH), which is a strong predictor of mortality in patients with endstage renal disease, is present in over 70% of patients commencing dialysis. However, only a few studies on LVH are available in patients before the start of dialysis treatment. The purpose of this study was to evaluate the prevalence and clinical correlates of LVH in patients with advanced stages of chronic kidney disease (CKD).<br>We performed a cross-sectional study of 90 patients who had renal diseases but no history of either cardiovascular diseases or arrhythmia. Circulating levels of human atrial natriuretic peptide (hANP) were also measured.<br>LVH was present in 40.0% of the study population. The prevalence of LVH tended to increase with progression of renal decline: 22.7% in stage 3, 43.6% in stage 4, and 48.3% in stage 5 (creatinine clearance>10mL/min) (p=0.15). Univariate analyses revealed that hANP and albumin were significantly different between the groups with and without LVH. Stepwise logistic regression analysis showed that hANP and albumin were selected as the independent risk factors.<br>These findings suggest that strict control of body fluid and nutrition could prevent the progression of LVH, and as a result, could attenuate the risk of cardiovascular events in CKD.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (19)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ